DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Keppra (Levetiracetam) - Published Studies

 
 



Keppra Related Published Studies

Well-designed clinical trials related to Keppra (Levetiracetam)

Levetiracetam in the treatment of alcohol dependence: toward the end of the story? [2012]

A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. [2012]

Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs. [2012]

The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial. [2011.07]

Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. [2011.06]

Evaluation of the subjective and reinforcing effects of diphenhydramine, levetiracetam, and valproic acid. [2011.06]

The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. [2011.05]

A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. [2011.05]

A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. [2011.04]

Levetiracetam in chronic daily headache: a double-blind, randomised placebo-controlled study. (The Australian KEPPRA Headache Trial [AUS-KHT]). [2011.04]

Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. [2011.02.01]

Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. [2011.02]

Spotlight on levetiracetam in epilepsy. [2011]

Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. [2011]

A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. [2011]

Levetiracetam for the treatment of alcohol withdrawal syndrome: a multicenter, prospective, randomized, placebo-controlled trial. [2010.12]

Intramuscular and intravenous levetiracetam in humans: safety and pharmacokinetics. [2010.10]

Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. [2010.09]

Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. [2010.07]

Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. [2010.05]

Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. [2010.04]

Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. [2010.04]

Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. [2010]

Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. [2010]

Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. [2010]

Levetiracetam in spinal cord injury pain: a randomized controlled trial. [2009.12]

Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. [2009.11]

Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques. [2009.10]

Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. [2009.07]

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. [2009.07]

Pilot study to evaluate the efficacy and tolerability of levetiracetam (Keppra) in treatment of patients with trigeminal neuralgia. [2009.06]

Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. [2009.06]

A prospective pilot study of levetiracetam for body dysmorphic disorder. [2009.05]

Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. [2009.05]

Effectiveness of levetiracetam in the treatment of lumbar radiculopathy: an open-label prospective cohort study. [2009.04]

Pharmacokinetics of levetiracetam XR 500mg tablets. [2009.04]

Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. [2009.03]

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. [2009.03]

The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. [2009.03]

Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. [2009.03]

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. [2009.03]

Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures. [2009.01.29]

Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. [2009]

Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures. [2009]

Bioequivalence of two formulations of levetiracetam. [2008.11]

Levetiracetam in absence epilepsy. [2008.11]

Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. [2008.09.12]

Effect of levetiracetam on the postmastectomy pain syndrome. [2008.08]

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. [2008.07.24]

Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study. [2008.06]

Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. [2008.04]

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. [2008.02.19]

Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. [2008.02]

Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. [2008.02]

Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study. [2008.02]

The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study. [2008]

Levetiracetam and bleeding disorders. [2007.12]

Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. [2007.11.27]

Levetiracetam is not effective for essential tremor. [2007.11]

Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. [2007.11]

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. [2007.10.30]

Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. [2007.10]

Impact of levetiracetam on mood and cognition during prednisone therapy. [2007.10]

A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. [2007.09.15]

Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. [2007.05]

Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. [2007.02.06]

Influence of levetiracetame on ictal and postictal EEG in patients with partial seizures. [2006.12]

Assessment of a dose-response relationship of levetiracetam. [2006.09]

Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. [2006.07]

Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. [2006.06.13]

Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. [2006.05]

Specific effect of levetiracetam in experimental human pain models. [2006.04]

Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA). [2006.03]

Effects of levetiracetam on nocturnal sleep and daytime vigilance in healthy volunteers. [2006.01]

Efficacy and Safety of Levetiracetam (up to 2000 mg/day) in Taiwanese Patients with Refractory Partial Seizures: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. [2006.01]

Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. [2006]

Effects of levetiracetam on sleep in normal volunteers. [2005.11]

Levetiracetam in social phobia: a placebo controlled pilot study. [2005.09]

Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. [2005.05]

The effect of levetiracetam on essential tremor. [2005.03.22]

Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. [2005.03]

Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar disorder. [2005.03]

Levetiracetam influences human motor cortex excitability mainly by modulation of ion channel function--a TMS study. [2004.11]

Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. [2004.11]

Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. [2004.10]

Levetiracetam: relative bioavailability and bioequivalence of a 10% oral solution (750 mg) and 750-mg tablets. [2003.12]

Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. [2003.05]

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. [2003.04]

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. [2003.02]

Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. [2003.02]

The effects of levetiracetam on objective and subjective sleep parameters in healthy volunteers and patients with partial epilepsy. [2002.09]

Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. [2002.07]

Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. [2002.05]

Levetiracetam: a different approach to the pharmacotherapy of epilepsy. [2002.02]

Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. [2002.01]

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. [2001.11]

Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. [2001.08]

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. [2000.12]

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. [2000.10]

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. [2000.09]

Comparison between the QOLIE-31 and derived QOLIE-10 in a clinical trial of levetiracetam. [2000.08]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017